Considering PDE5 inhibitors’ (PDE5is) potent vasoactive effects, which result in vasodilatation, PDE5is are now licensed for the treatment of ED and pulmonary artery hypertension (PAH). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.